MX2018008557A - Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. - Google Patents

Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.

Info

Publication number
MX2018008557A
MX2018008557A MX2018008557A MX2018008557A MX2018008557A MX 2018008557 A MX2018008557 A MX 2018008557A MX 2018008557 A MX2018008557 A MX 2018008557A MX 2018008557 A MX2018008557 A MX 2018008557A MX 2018008557 A MX2018008557 A MX 2018008557A
Authority
MX
Mexico
Prior art keywords
n3pglu
amyloid beta
beta peptide
peptide antibodies
antibodies
Prior art date
Application number
MX2018008557A
Other languages
English (en)
Inventor
Lu Jirong
Tang Ying
Bradley Demattos Ronald
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018008557A publication Critical patent/MX2018008557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Anticuerpos para Aß N3pGIu humano, composiciones que comprenden tales anticuerpos Aß N3pGlu y métodos para usar tales anticuerpos Aß N3pGlu para el tratamiento de una enfermedad caracterizada por deposición de Aß que incluye enfermedad de Alzheimer clínica o pre-clínica, síndrome de Down y angiopatía amiloide cerebral clínica o pre-clínica.
MX2018008557A 2016-01-15 2017-01-10 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. MX2018008557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662279268P 2016-01-15 2016-01-15
PCT/US2017/012795 WO2017123517A1 (en) 2016-01-15 2017-01-10 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2018008557A true MX2018008557A (es) 2018-09-18

Family

ID=57966094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008557A MX2018008557A (es) 2016-01-15 2017-01-10 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.

Country Status (17)

Country Link
US (1) US9944696B2 (es)
EP (1) EP3402817B1 (es)
JP (1) JP6634158B2 (es)
KR (1) KR102141969B1 (es)
CN (2) CN108473566B (es)
AR (1) AR107290A1 (es)
AU (1) AU2017207250B2 (es)
BR (1) BR112018011308A2 (es)
CA (1) CA3007000C (es)
EA (1) EA037784B1 (es)
ES (1) ES2968255T3 (es)
IL (1) IL259748B2 (es)
JO (1) JOP20170004B1 (es)
MX (1) MX2018008557A (es)
TW (1) TWI634126B (es)
WO (1) WO2017123517A1 (es)
ZA (1) ZA201901207B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CR20210492A (es) 2019-03-26 2021-11-19 Janssen Pharmaceutica Nv ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
TW202243690A (zh) 2021-01-11 2022-11-16 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023076970A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
JP2023067832A (ja) 2021-10-29 2023-05-16 イーライ リリー アンド カンパニー インターロイキン－３４を標的とする化合物及び方法
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
MX2010013647A (es) 2008-06-12 2011-04-05 Affiris Ag Compuestos para tratar sintomas asociados con la enfermedad de parkinson.
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
PL3339323T3 (pl) * 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
AU2014233615B2 (en) * 2010-08-12 2016-08-11 Eli Lilly And Company Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples

Also Published As

Publication number Publication date
AU2017207250A1 (en) 2018-06-07
BR112018011308A2 (pt) 2018-11-27
EA037784B1 (ru) 2021-05-20
KR102141969B1 (ko) 2020-08-06
IL259748B2 (en) 2023-03-01
CN114891100B (zh) 2024-05-03
TWI634126B (zh) 2018-09-01
KR20180086268A (ko) 2018-07-30
CN114891100A (zh) 2022-08-12
US20170204171A1 (en) 2017-07-20
CN108473566A (zh) 2018-08-31
EA201891286A1 (ru) 2018-12-28
AR107290A1 (es) 2018-04-18
IL259748A (en) 2018-07-31
EP3402817A1 (en) 2018-11-21
ZA201901207B (en) 2022-05-25
ES2968255T3 (es) 2024-05-08
CN108473566B (zh) 2022-06-17
JP2019507107A (ja) 2019-03-14
AU2017207250B2 (en) 2019-04-18
EP3402817B1 (en) 2023-10-18
TW201739761A (zh) 2017-11-16
CA3007000C (en) 2021-07-27
JP6634158B2 (ja) 2020-01-22
WO2017123517A1 (en) 2017-07-20
CA3007000A1 (en) 2017-07-20
IL259748B (en) 2022-11-01
JOP20170004B1 (ar) 2022-09-15
US9944696B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
PH12017500032A1 (en) Improved a� protofibril binding antibodies
BR112016023948A2 (pt) proteínas fc multiméricas
MX2023001299A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
MX2022005655A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
EA201690159A1 (ru) Способы и композиции для лечения рака
EP3411504A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE-1 DIABETES
WO2017049038A3 (en) Anti-cd115 antibodies
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
EP3589645C0 (en) CYCLIC PEPTIDES FOR THE TREATMENT OF BASEDOW'S DISEASE
IL251024A0 (en) Antibodies against eutaxin 2 for use in the treatment of liver diseases
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
GB201819758D0 (en) Medicine for the treatment of Alzheimer's disease